// App-Quantinova.ai

: Durvalumab (MEDI 4736) with extended neoadjuvant regimens in rectal cancer: A randomised phase II trial (PRIME-RT).

Researchers

Presenter

  • Campbell SD Roxburgh

Principal Investigators

  • Janet Graham

  • Mark P. Saunders

  • Leslie M. Samuel

  • Nicholas James MacLeod

  • Lynsey Devlin

  • Joanne Edwards

  • Lily Hillson

  • Ross K McMahon

  • Leia Ashleigh Jones

  • Caroline Kelly

  • Liz-Anne Lewsley

  • Paula Morrison

  • Peter Atherton

  • Nicola Walker

  • Jacqueline Gourlay

  • Ellie Tiplady

  • Richard Adams

  • Sean Michael O'Cathail

Medical Centers

  • The Beatson Cancer Centre, Glasgow, United Kingdom

  • Cancer Research UK Glasgow Clinical Trials Unit, Glasgow, United Kingdom

  • Beatson WOSCC, Glasgow, United Kingdom

  • University of Glasgow, Glasgow, United Kingdom

  • CR-UK Clinical Trials Unit, Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

  • Velindre Cancer Centre, Cardiff, United Kingdom

  • University of Glasgow, Glasgow, United Kingdom

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • Aberdeen Royal Infirmary, Aberdeen, United Kingdom

  • NHS Greater Glasgow & Clyde, Glasgow, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Colorectal Cancer

Biomarkers

  • C-C Motif Chemokine Ligand 20

Drug/Treatment

  • Capecitabine

  • Durvalumab

  • Oxaliplatin, 5-fluorouracil and folic acid

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Multicenteric

Phase

  • II

Study Id's

  • ISRCTN18138369

  • NCT04621370

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved